argenex (NASDAQ:ARGX) Receives Outperform Rating from Wedbush

argenex (NASDAQ:ARGX - Get Free Report)'s stock had its "outperform" rating reissued by Wedbush in a research report issued to clients and investors on Monday,RTT News reports. They presently have a $715.00 price target on the stock. Wedbush's target price suggests a potential upside of 24.81% from the stock's current price. Wedbush also issued estimates for argenex's Q2 2025 earnings at $3.41 EPS and Q3 2025 earnings at $4.22 EPS.

Other equities analysts have also recently issued research reports about the company. Baird R W upgraded argenex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Morgan Stanley began coverage on argenex in a report on Thursday, July 3rd. They issued an "overweight" rating and a $700.00 price target on the stock. Citigroup reiterated a "buy" rating on shares of argenex in a report on Wednesday, May 21st. Guggenheim decreased their price target on argenex from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $720.00 price target on shares of argenex in a report on Tuesday, July 1st. Nineteen analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, argenex presently has an average rating of "Buy" and an average target price of $728.06.

argenex Price Performance

Shares of NASDAQ:ARGX traded up $1.66 during midday trading on Monday, reaching $572.89. The company's stock had a trading volume of 181,852 shares, compared to its average volume of 329,863. argenex has a fifty-two week low of $460.05 and a fifty-two week high of $678.21. The company has a market capitalization of $35.06 billion, a P/E ratio of 35.31, a P/E/G ratio of 0.98 and a beta of 0.37. The business's fifty day simple moving average is $564.59 and its 200-day simple moving average is $599.19.

argenex (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. argenex had a return on equity of 16.15% and a net margin of 40.20%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $748.34 million. On average, analysts forecast that argenex will post 3.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On argenex

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Europe London LLP acquired a new position in shares of argenex during the 4th quarter worth approximately $5,839,000. Ameriprise Financial Inc. increased its position in shares of argenex by 10.0% during the 4th quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company's stock worth $4,313,000 after purchasing an additional 639 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of argenex by 21.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,214 shares of the company's stock worth $2,592,000 after acquiring an additional 755 shares during the last quarter. Sowell Financial Services LLC acquired a new position in shares of argenex during the 1st quarter worth approximately $332,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of argenex by 21.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 24,929 shares of the company's stock worth $15,332,000 after acquiring an additional 4,445 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.